Literature DB >> 9815027

5-HT4 receptor agonists and delta-opioid receptor antagonists act synergistically to stimulate colonic propulsion.

A E Foxx-Orenstein1, J G Jin, J R Grider.   

Abstract

Opioid neurons exert a tonic restraint on inhibitory VIP/PACAP/NOS motoneurons of the enteric nervous system. A decrease in opioid peptide release during the descending phase of the peristaltic reflex, which underlies propulsive activity, leads to an increase in vasoactive intestinal peptide (VIP), pituitary adenylate cyclase-activating polypeptide (PACAP), and nitric oxide (NO) release and circular muscle relaxation. These effects are accentuated by opioid receptor antagonists. Endogenous opioid peptides and selective opioid delta-, kappa- and mu-receptor agonists decreased the velocity of pellet propulsion in isolated segments of guinea pig colon, whereas selective antagonists increased velocity in a concentration-dependent fashion with an order of potency indicating preferential involvement of delta-receptors. 5-HT4 agonists (HTF-919 and R-093877), which also increase the velocity of propulsion, acted synergistically with the delta-receptor antagonist naltrindole; a threshold concentration of naltrindole (10 nM) shifted the concentration-response curve to HTF-919 to the left by 70-fold. A combination of 10 nM naltrindole with threshold concentrations of the 5-HT4 agonists caused significant increases in the velocity of propulsion (50 +/- 7 to 77 +/- 8%). We conclude that 5-HT4 agonists and opioid delta-receptor antagonists act synergistically to facilitate propulsive activity in isolated colonic segments.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9815027     DOI: 10.1152/ajpgi.1998.275.5.G979

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  20 in total

1.  Bifunctional μ/δ opioid peptides: variation of the type and length of the linker connecting the two components.

Authors:  Jinguo Ding; Carole Lemieux; Nga N Chung; Peter W Schiller
Journal:  Chem Biol Drug Des       Date:  2012-01-04       Impact factor: 2.817

Review 2.  Treating irritable bowel syndrome: overview, perspective and future therapies.

Authors:  Michael Camilleri
Journal:  Br J Pharmacol       Date:  2004-03-22       Impact factor: 8.739

3.  Gastrointestinal Motility Monitor (GIMM).

Authors:  Jill M Hoffman; Elice M Brooks; Gary M Mawe
Journal:  J Vis Exp       Date:  2010-12-01       Impact factor: 1.355

Review 4.  Opioid ligands with mixed mu/delta opioid receptor interactions: an emerging approach to novel analgesics.

Authors:  Subramaniam Ananthan
Journal:  AAPS J       Date:  2006-03-10       Impact factor: 4.009

5.  Evolution of the Bifunctional Lead μ Agonist / δ Antagonist Containing the Dmt-Tic Opioid Pharmacophore.

Authors:  Gianfranco Balboni; Severo Salvadori; Claudio Trapella; Brian I Knapp; Jean M Bidlack; Lawrence H Lazarus; Xuemei Peng; John L Neumeyer
Journal:  ACS Chem Neurosci       Date:  2010-02-17       Impact factor: 4.418

6.  Inflammation-associated changes in DOR expression and function in the mouse colon.

Authors:  Jesse J DiCello; Ayame Saito; Pradeep Rajasekhar; Emily M Eriksson; Rachel M McQuade; Cameron J Nowell; Benjamin W Sebastian; Jakub Fichna; Nicholas A Veldhuis; Meritxell Canals; Nigel W Bunnett; Simona E Carbone; Daniel P Poole
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2018-06-21       Impact factor: 4.052

7.  Do elevated plasma vasoactive intestinal polypeptide (VIP) levels cause small intestinal motor disturbances in humans?

Authors:  Jutta Keller; Jan C Mueller-Wolf; Keihan Ahmadi-Simab; Christiane Fibbe; Ulrich Rosien; Peter Layer
Journal:  Dig Dis Sci       Date:  2005-02       Impact factor: 3.199

8.  Synthesis, modeling, and pharmacological evaluation of UMB 425, a mixed μ agonist/δ antagonist opioid analgesic with reduced tolerance liabilities.

Authors:  Jason R Healy; Padmavani Bezawada; Jihyun Shim; Jace W Jones; Maureen A Kane; Alexander D MacKerell; Andrew Coop; Rae R Matsumoto
Journal:  ACS Chem Neurosci       Date:  2013-06-11       Impact factor: 4.418

Review 9.  Bi- or multifunctional opioid peptide drugs.

Authors:  Peter W Schiller
Journal:  Life Sci       Date:  2009-03-11       Impact factor: 5.037

10.  Chronic Intestinal Pseudoobstruction.

Authors:  Greg Lyford; Amy Foxx-Orenstein
Journal:  Curr Treat Options Gastroenterol       Date:  2004-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.